Nomogram use for the prediction of indolent prostate cancer

Screening for prostate cancer has resulted in an increased incidence‐to‐mortality ratio. Not all cancers deserve immediate treatment. It has therefore become more important to be able to identify those cases of screen‐detected prostate cancer most likely to show indolent behavior.

[1]  E W Steyerberg,et al.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. , 2006, The Journal of urology.

[2]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[3]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[4]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[5]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[6]  Daniel O Scharfstein,et al.  Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. , 2005, Urology.

[7]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[8]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[9]  L. Klotz.  Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. , 2005, The Canadian journal of urology.

[10]  M. Roobol,et al.  Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) , 2003, BJU international.

[11]  Hartwig Huland,et al.  Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. , 2003, The Journal of urology.

[12]  Hongyu Wu,et al.  Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[14]  T. Stamey,et al.  Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. , 2001, The Journal of urology.

[15]  P. Walsh,et al.  Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. , 1997, The Journal of urology.

[16]  M W Kattan,et al.  Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. , 1996, The Journal of urology.

[17]  T. Stamey,et al.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.

[18]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[19]  L. Klotz.  Active surveillance with selective delayed intervention for favorable risk prostate cancer. , 2006, Urologic oncology.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.